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Abstract 
Background 
Longitudinal follow-up studies in patients with idiopathic 
rapid-eye-movement sleep behaviour disorder (iRBD) have shown 
that the majority eventually develop the synucleinopathies 
Parkinson’s disease, dementia with Lewy bodies or multiple 
system atrophy. Neuroinflammation in the form of microglial 
activation is present in synucleinopathies and provides a 
possible therapeutic target to halt or delay the 
neurodegenerative process.  This prospective case-control 
positron emission tomography (PET) study investigates whether 
neuroinflammation is present in iRBD and its possible relation 
to nigrostriatal dopamine function.  
 
Methods 
Twenty consecutive patients with polysomnography-confirmed 
iRBD and no clinical evidence of parkinsonism and cognitive 
impairment were recruited between March 2015 and October 2016 
in our tertiary sleep centres in Spain (Barcelona) and Denmark 
(Aarhus). We assessed levels of microglial activation in the 
substantia nigra, putamen, and caudate using 11C-PK11195 PET 
and dopamine terminal function in putamen and caudate with 18F-
DOPA PET. Nineteen healthy controls underwent either 11C-
PK11195 PET (n=10) or 18F-DOPA PET (n=9) for comparison. 
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Findings  
11C-PK11195 binding was increased in the substantia nigra of 
iRBD patients compared to controls on the left side (Student’s 
t test, mean difference = 0153, 95% CI [0055 to 0250], 
p=0003) but not on the right side (0121, [-0007 to 0250], 
p=0064). 11C-PK11195 binding was not significantly increased in 
the putamen and caudate of iRBD patients. 18F-DOPA uptake was 
reduced in iRBD in the left (-00032, [-00044 to -00021], 
p<00001) and right putamen (-00032, [-00044 to -00020], 
p<00001) but not in the caudate nuclei.  
 
Interpretation  
In patients with iRBD, PET imaging detects increased 
microglial activation in the substantia nigra along with 
reduced putamen dopaminergic function. Further studies 
including more subjects and longitudinal follow-up of the 
present patients are needed to support our current findings 
and evaluate if the presence of activated microglia in iRBD 
represents a marker of short-term conversion to a clinically 
defined synucleinopathy. 
 
 
Funding 
The study was funded by the Danish Council for Independent 
Research and the Spanish Instituto de Salud Carlos III. 
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Background 
 
Parkinson disease (PD), dementia with Lewy bodies (DLB), and 
multiple system atrophy (MSA) are three progressive 
neurodegenerative disorders characterised by abnormal 
aggregation and accumulation of the protein -synuclein in 
neurons, neurites, or oligodendroglial cells and dopamine 
deficiency in the nigrostriatal system. Accumulative data 
indicate that the aggregation of -synuclein in affected 
individuals occurs years before the occurrence of the cardinal 
symptoms of these disorders, namely parkinsonism and 
dementia.1,2 Therefore, the identification of subjects in the 
prodromal phase of these diseases, along with detection of 
biomarkers showing early pathological changes indicating 
manifest disease, is a high priority. This may contribute to 
the rational development of therapeutic strategies to halt or 
delay disease progression in its earliest stages.3 
Rapid-eye-movement (REM) sleep behaviour disorder (RBD) is a 
parasomnia characterized by dream-enacting behaviours, 
nightmares and lack of muscle atonia during REM sleep. 
Available data indicate that the idiopathic form of RBD (iRBD) 
precedes the development of PD, DLB, and much more rarely 
MSA.4-6 Prospective studies of iRBD patients show a risk of 41% 
for progression to PD or DLB within 5 years from iRBD 
diagnosis (cohort size n=279), and up to 91% by 14 years 
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(cohort size n=174).4 Imaging studies in iRBD patients have 
detected findings similar to those observed in patients with 
established PD and DLB such as impaired integrity of the 
dopaminergic nigrostriatal pathway.7-9 Additionally, Lewy type 
pathology, a neuropathological hallmark of PD and DLB, has 
been observed in the brains of iRBD cases.10,11   
Neuroinflammation, a possible disease-causing mechanism that 
is present in patients manifesting synucleinopathies has not 
been investigated in iRBD with in vivo molecular imaging. 
Using 11C-PK11195 positron emission tomography (PET), an in 
vivo marker of microglial activation, several studies have 
shown increased brain signal in manifest PD, DLB, and MSA.12-15 
Microglia are the resident immune cells of the central nervous 
system, and account for the intrinsic inflammatory response to 
neuronal damage. It is thought that protracted activation of 
microglia cells may contribute to the development and 
progression of the neurodegenerative process.16 Modulation of 
microglial activation could provide a potential therapeutic 
strategy for slowing disease progression, particularly in its 
earliest stages.17-20   
The objective of this in vivo PET imaging study was to examine 
the hypothesis that patients with iRBD show increased 
nigrostriatal levels of activated microglia as part of the 
neuropathological process. Additionally, we aimed to 
investigate the relationship between neuroinflammation and 
6 
 
dopaminergic function in nigrostriatal structures in iRBD 
patients.  
 
 
Methods 
 
Study population 
 
This prospective case-control study was conducted between 
March 23rd, 2015, and October 19th, 2016. Twenty consecutive 
patients with polysomnography-confirmed iRBD according to 
established criteria17 were recruited from tertiary Sleep 
Clinics at Aarhus University Hospital, Denmark (n=10) and the 
Multidisciplinary Sleep Unit of the Hospital Clínic de 
Barcelona, Spain (n=10). Prior to inclusion, patients 
underwent a full clinical history and examination to exclude a 
neurological condition.18-20 None of the patients had motor or 
cognitive complaints. A healthy control group consisting of 
nineteen subjects who had no motor or cognitive complaints, a 
normal neurological examination, and a mean group age similar 
to the iRBD group were recruited to participate in the current 
study through newspaper advertisements (44 subjects responded, 
the first eligible subjects were included). They were randomly 
selected to receive either 11C-PK11195 PET (n=10) or 18F-DOPA 
PET (n=9). Absence of RBD symptoms in the controls was 
screened by a questionnaire21, and a comprehensive clinical 
7 
 
history of the individuals and their bed-partner. None of the 
included subjects were regular users of anti-inflammatory 
drugs or were taking antidepressants at the time of this 
study. 
The study received approval from the local Ethics Committee at 
both centers. All subjects gave informed written consent 
according to the Declaration of Helsinki before enrolment into 
the study. 
 
 
PET and MRI imaging 
 
All subjects had PET imaging at the Department of Nuclear 
Medicine & PET Centre, Aarhus University Hospital, Denmark. 
Dynamic PET scans were performed with a Siemens High-
Resolution Research Tomograph (ECAT HRRT; CTI/Siemens). 
Patients from Spain flew to Denmark to undergo PET studies.  
11C-PK11195 PET was used to assess levels and extent of brain 
microglial activation and 18F-DOPA PET to assess nigrostriatal 
dopamine function.  
Patients had the PET studies over two separate days while 
control subjects had either 11C-PK11195 PET or 18F-DOPA PET to 
reduce their radiation exposure. Detailed information on PET 
scanning procedure is provided in online appendix.  
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Participants had a structural MRI 3D T1 MP2RAGE sequence for 
co-registration of the PET images (3 T MAGNETOM Skyra, Siemens 
Healthcare). 
 
 
Image analysis 
 
PET images were analysed using regions of interest (ROI) with 
the PNEURO module of PMOD software v 3.6 (PMOD technologies 
Ltd. Switzerland). The following predefined regions of 
interest were investigated: Substantia nigra, dorsal putamen 
(posterior to the anterior commissure), and the caudate 
nucleus. However, since 18F-DOPA PET is a marker of dopamine 
nigrostriatal terminal function rather than perikarya 
integrity the substantia nigra ROI was only used to sample 11C-
PK11195 binding.  
Parametric images of regional 11C-PK11195 binding potentials 
(BPND) (Figure 1) were generated using individual reference 
tissue non-specific input functions and the simplified 
reference tissue model.22 Microglia activation can potentially 
be present throughout the brain in subjects with 
neurodegenerative disorders. Given this, one cannot be 
confident that a reference tissue region devoid of specific 
ligand binding is present. We, therefore, used a supervised 
cluster-analysis approach to extract brain voxels behaving 
kinetically similar to normal grey matter as a reference 
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tissue input function for each individual subject. Since this 
method can be sensitive to error, similarity between extracted 
reference tissue input functions from patients and controls 
were assessed with a repeated measurement analysis (χ2 > 005), 
as previously described.12,14,15,22 The supervised cluster 
analysis model estimates tracer binding in ROIs relative to a 
cluster of reference voxels behaving kinetically similar to 
normal grey matter tissue. In this model, target voxels with 
binding lower than the reference cluster will provide negative 
binding potential values.  
Parametric images of 18F-DOPA influx constants (Ki) (Figure 1) 
were generated with the Patlak graphical approach23 using 
occipital lobe grey matter as a non-specific reference tissue 
input function.24 See online appendix for details on MRI and 
PET images co-registration and normalisation.  
A threshold for abnormality in regional 11C-PK11195 binding and 
18F-DOPA uptake was defined as a statistical deviation from the 
norm. Briefly, regional 11C-PK11195 binding were classified as 
abnormal when the BPND was two or more standard deviations 
above the control mean (z-score ≥ 2) - the control values from 
both left and right side were averaged. Patients were 
classified as having abnormal regional 18F-DOPA uptake when 
their Ki values fell below two or more standard deviations 
from the controls mean value (z-score ≤ -2).25  
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Statistical analysis 
 
Statistical calculations and graphical presentations were 
performed using Stata IC 14 (StataCorp LP. Texas, USA) and 
PRISM 6 (GraphPad, Software, La Jolla, CA). Normal 
distribution of outcome measures (18F-DOPA Ki-values and 11C-
PK11195 BPND) was assessed with normal probability plots and 
checked with the D’Agostino-Pearson normality test. Grubbs 
test was used to exclude any possible outliers. Between-group 
comparisons for continuous data of 18F-DOPA Ki-values and 11C-
PK11195 BPND in predefined ROIs were interrogated with an 
unpaired two-tailed Student’s t test (alpha=50%). Welch’s 
correction was used for data with unequal variances. Two-
tailed Pearson product-moment correlations (alpha=50%) were 
used to assess relationship between ROIs and tracers. In 
details, we first assessed the relationship between levels of 
11C-PK11195 binding in the substantia nigra and striatal 
structures due to their anatomical connection. We then 
assessed the relationship between levels of 11C-PK11195 
binding in the substantia nigra and 18F-dopa uptake in the 
putamen and caudate to investigate whether higher 
neuroinflammation around the nigral dopamine cell bodies 
correlated with more severe dopaminergic dysfunction in 
striatal areas due to terminal dysfunction. Finally, we 
investigate possible correlations between neuroinflammation 
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and dopaminergic terminal dysfunction within the striatal 
areas. 
 
 
 
Role of the funding source 
 
The funding source had no influence on the study design, 
collection, analysis and interpretation of data, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication. 
 
 
Results 
 
Demographics and clinical characteristics of iRBD patients and 
controls are reported in Table 1. There were no differences in 
age between patients and controls. No adverse events occurred 
during the study. 
 
11C-PK11195 binding was significantly increased in the left 
substantia nigra of the iRBD patients compared to controls 
(mean difference = 0153, 95% CI [0055 to 0250], p=0003) and 
not in the right nigra (0121, [-0007 to 0250], p=0064). The 
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iRBD group showed no differences in mean 11C-PK11195 binding in 
the putamen and caudate nucleus bilaterally (Putamen left; 
0047, [-0068 to 0161], p=041 and right; 0044, [-0074 to 
0163], p=045. Caudate left; 0076, [-0053 to 0205], p=024 and 
right; 0024, [-0098 to 0147], p=069) (Table 2).  
Individual analysis showed that 7/20 (35%) iRBD patients had 
abnormally raised 11C-PK11195 binding in the substantia nigra, 
and 2/20 (10%) in the putamen and caudate nucleus (Table 3). 
One subject had bilateral abnormal binding in all three 
regions investigated; substantia nigra, putamen, and caudate 
nucleus. 
 
18F-DOPA uptake was reduced in the putamen bilaterally in the 
iRBD patients compared to controls (left; -00032, [-00044] to 
-00021, p<00001 and right; -00032, [-00044 to -00020], 
p<00001). The average putaminal decrease in the iRBD group was 
246% (95% CI 186 to 306). No changes in 18F-DOPA uptake where 
observed in the caudate nucleus at the group-level (left; -
00012, [-00025 to 000006], p=006 and right; -00009, [-00022 
to 0003], p=01)(Table 2). 
At an individual level, 18/20 (90%) iRBD patients had 
abnormally reduced 18F-DOPA uptake in the putamen in one or 
both sides and 7/20 (35%) patients had reduced 18F-DOPA uptake 
in the caudate nucleus (Table 3). All seven patients with 
reduced 18F-DOPA uptake in the caudate nucleus also had reduced 
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putaminal uptake ipsilaterally. Six of these seven patients 
had bilateral abnormally reduced uptake throughout the 
striatum.   
 
In the iRBD cohort, increased 11C-PK11195 binding in the 
substantia nigra correlated positively with increased binding 
of 11C-PK11195 in the ipsilateral putamen (left; Pearson 
coefficient r = 0·59, 95% CI [0·20 to 0·82], p=0·006 and 
right; 0·62, [0·24 to 0·83], p=0·004), and in the caudate 
nucleus on the right side (left; = 0·34, 95% CI [-0·12 to 
0·68], p=0·1 and right; 0·55, [0·15 to 0·80], p=0·01)(Figure 
2). Increased 11C-PK11195 binding in the left substantia nigra 
correlated significantly with decreased 18F-DOPA uptake in the 
ipsilateral caudate nucleus on the left side (Left r -0·53, [-
0·79 to -0·11], p=0·02 (Figure 2). No significant correlations 
were found between right substantia nigra 11C-PK11195 binding 
and 18F-DOPA uptake in the right caudate (r -0·13, [-0·54 to 
0·33], p=0·6) or between substantia nigra 11C-PK11195 binding 
and 18F-DOPA uptake in the ipsilateral putamen (left; = -0·26, 
95% CI [-0·63 to 0·21], p=0·3 and right; -0·03, [-0·46 to 
0·42], p=0·9)(Figure 2).  
Within the striatum, no significant correlations were found 
between 11C-PK11195 binding and 18F-DOPA uptake in the putamen 
(left; = -0·23, 95% CI [-0·61 to 0·23], p=0·3 and right; -
0·23, [-0·61 to 0·23], p=0·3)(Figure 2). In the caudate 
nucleus, a significant correlation was seen only on the left 
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side (left r = -0·47, 95% CI [-0·75 to -0·03], p=0·04; right r 
= -0·28, [-0·64 to 0·19], p=0·2)(Figure 2). 
 
The analysis of individuals revealed that all seven patients 
with abnormally raised 11C-PK11195 binding in the substantia 
nigra also had abnormally reduced 18F-DOPA uptake in the 
ipsilateral putamen. One patient had bilaterally abnormal 
increased 11C-PK11195 binding in the substantia nigra, putamen, 
and caudate nucleus and decreased 18F-DOPA uptake in the 
putamen and caudate nucleus. Six patients had reduced 18F-DOPA 
uptake in the putamen but their 11C-PK11195 binding in the 
ipsilateral substantia nigra was below the upper limit of the 
95% CI of control subjects. 
No significant correlation was observed between 11C-PK11195 
binding within the substantia nigra and patient reported 
duration of RBD (r = 0·2, [-0·28 to 0·58], p=0·4) or from time 
of iRBD diagnosis to PET examination(r = 0·3, [-0·18 to 0·65], 
p=0·2). 
 
 
Discussion 
 
This study represents the first in vivo observations 
indicating that raised microglial activation in iRBD is an 
early component in the neurodegenerative process along with 
reduced nigrostriatal dopaminergic function. 
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The current study showed a larger degree of neuroinflammation 
in the substantia nigra than the striatum in iRBD patients. 
This was the case for both the group level analysis and on an 
individual level where 7/20 (35%) subjects had raised 11C-
PK11195 binding in the substantia nigra compared to 2/20 (10%) 
subjects in the putamen and caudate nucleus (Table 3). 
Previous 11C-PK11195 PET studies in patients with PD, DLB, or 
MSA,12,14,15,26 have reported raised levels of microglia 
activation in the striatum with less consistent involvement of 
the substantia nigra.12,14 Patients with higher levels of 
microglia activation in the substantia nigra also displayed 
higher 11C-PK11195 binding in the ipsilateral putamen. This 
could reflect the dysfunction of dopaminergic terminals and 
synapses associated with pathological changes in the 
dopaminergic neurons of the substantia nigra.  
 
Significantly decreased levels of 18F-DOPA uptake were found in 
the putamen of our iRBD patients. This supports findings of 
previous studies investigating iRBD patients, using ligands 
for the dopamine transporter (DaT) to measure the integrity of 
nigrostriatal dopaminergic function.8,27-30 In our analysis of 
individual subjects 18/20 (90%) had reduced putaminal 18F-DOPA 
uptake on at least one side and 14/20 (70%) bilaterally (Table 
3). This represents a higher frequency of patients with a 
dopaminergic decrement than that reported across the majority 
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of previous series where 30-40% of the iRBD patients had an 
abnormal DaT-single photon computed emission tomography 
(SPECT).8,27,29-32 This may be explained by the use of high-
resolution PET imaging with delineation of regions of interest 
for each individual from their MRI. The mean decrease of 246% 
in putaminal 18F-DOPA uptake in iRBD patients compared to 
controls is in line with studies on Hoehn and Yahr stage 1 
unilateral early PD cases which have reported a 20-35% 
putaminal reduction contralateral to the non-affected limbs 
and a 43-52% decrease contralateral to the affected limbs.33  
At the group-level, we observed no reduction of mean 18F-DOPA 
uptake in the caudate nucleus. This is in line with the fact 
that dopaminergic function remains relatively preserved in the 
caudate nucleus when compared with the putamen in patients 
with early PD.34 However, some individual subjects were noted 
to have a decrement in the caudate, which also has been 
observed in DaT-SPECT studies by others.8,29,30 Currently, it is 
unknown if a greater reduction in 18F-DOPA uptake in the 
caudate nucleus and putamen in individual subjects is a short-
term marker for conversion towards a specific type of 
synucleinopathy. 
 
We found a significant correlation between raised 11C-PK11195 
binding in the substantia nigra and reduced 18F-DOPA uptake in 
the ipsilateral caudate nucleus. This finding might relate to 
potential progression in some of our cases to DLB, where a 
17 
 
more pronounced involvement of the caudate nucleus is 
observed.35 
We did not find any significant correlations between raised 
11C-PK11195 binding in the substantia nigra or the putamen and 
reduced 18F-DOPA uptake in the ipsilateral putamen (Figure 
2C+D). This accord with similar observations between 11C-
PK11195 and 18F-DOPA within nigrostriatal structures in 
patients with PD.12 
Interestingly, while abnormally raised levels of microglial 
activation in the substantia nigra were only seen in a 
subgroup 7/20(35%) of our iRBD patients, we found all these 
patients to have reduced 18F-DOPA uptake in the ipsilateral 
putamen. Recent reports have suggested that impaired 
intracellular trafficking, including dopamine function in the 
terminals may be an early abnormal phenomenon occurring in PD 
development.36,37 This assumption might explain our observation 
of reduced putaminal 18F-DOPA uptake in the absence of 
detectable nigral microglial activation in some iRBD patients. 
 
The pathogenesis of PD is complex involving a variety of 
genetic, environmental, cellular, and molecular factors.  
There is mounting evidence that the immune system plays an 
important role since microglial and also astroglial activation 
are present and have a deleterious effect on neuronal 
function.38 Moreover, epidemiologic studies have shown reduced 
risk of developing PD in users of non-aspirin non-steroidal 
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anti-inflammatory drugs39 and pharmacological immunosuppression 
can reduce neurodegeneration in rodent models of PD.40 
Consequently, research efforts have focused on 
neuroinflammation as a therapeutic target in early manifested 
PD. Our current finding of neuroinflammation occurring in the 
central nervous system of iRBD patients sheds light on the 
early pathological events occurring in disorders associated to 
Lewy type pathology. However, the cross-sectional nature of 
our study does not enable to clarify whether neuroinflammation 
is a primary event in the neurodegenerative process or whether 
neuronal dysfunction leads to secondary neuroinflammation. 
  
This study has some limitations. First, the size of our cohort 
is relatively small. Therefore, our findings need to be 
confirmed in larger cohorts of patients. Second, this PET 
study used 11C-PK11195 as a marker of translocator protein 
(TSPO) expressed by activated microglia cells and astrocytes 
rather than one of the newer TSPO tracers available. This has 
enabled us to compare our 11C-PK11195 PET findings with those 
of previous studies of microglial activation in 
synucleinopathies. Additionally, 11C-PK11195 binding affinity 
is not influenced by the TSPO polymorphism carried by 
individuals. This is an issue with the newer tracers where 
exclusion of patients with low or mixed-affinity binding can 
potentially lead to a selection bias. We acknowledge, however, 
that 11C-PK11195 provides a lower specific to background signal 
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ratio than newer microglial markers and our results might 
underestimate the true extent of microglia activation, 
particularly in the case of subtle increases. Another possible 
limitation of the study is that the healthy controls were 
self-referred as they responded to newspaper advertisements. 
However, they had to fulfil all the inclusion/exclusion 
criteria and they were randomly selected to receive either 11C-
PK11195 PET or 18F-DOPA PET. 
Finally, in this study we have assumed that a raised level of 
microglial activation is pathogenic. This assumption is at 
variance with a recent published study in early Alzheimer’s 
disease where it was reported that raised microglial 
activation appeared to have a protective effect.41 Longitudinal 
follow-up of our iRBD individuals will reveal the clinical 
significance of the current observations. 
 
In summary, we have shown that raised microglial activation in 
the substantia nigra and reduced presynaptic nigrostriatal 
dopaminergic function can be detected in iRBD patients using a 
combination of 11C-PK11195 and 18F-DOPA PET. This result implies 
that neuroinflammation and dopaminergic deficit occurs in iRBD 
patients, a condition that represents the prodromal stage of 
the synucleinopathies. Further studies involving larger series 
of iRBD subjects are needed to support our current 
observations and long-term follow-up with clinical and 
neuroimaging assessment of these patients may elucidate 
20 
 
whether the raised levels of microglial activation in iRBD 
represents a marker of short-term conversion to clinically 
defined synucleinopathies. 
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Tables 
Table 1 
Characteristics and demographics of study population   
 iRBD 
(n=20) 
Controls 
11C-PK11195 
(n=10) 
 
 
Controls 
18F-DOPA 
(n=9) 
 
Age (years) 
66·6 (6·3) 
 
65·8 (4·3) 
 
64·6 (3·6) 
Sex 
     Male 
     Female 
 
17 (85%) 
3 (15%) 
 
10 (100%) 
- 
 
9 (100%) 
- 
iRBD follow-up duration (years) 3·8 (3·4) 
 
-  
Age at iRBD diagnosis (years) 62·8 (6·2) 
 
-  
Duration of iRBD symptoms at PET 
examination 
9·4 (5·3) 
 
-  
11C-PK11195 PET 20 10 0 
18F-DOPA PET 
20 0 9 
 
Data are mean (standard deviation) or n (%). 
iRBD = idiopathic REM sleep behaviour disorder. 
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Table 2 
11C-PK11195 BPND and 18F-DOPA Ki values for iRBD patients and 
controls  
 
 11C-PK11195 18F-DOPA 
 iRBD 
n=20 
Controls 
n=10 
Difference between 
iRBD and controls 
P value iRBD 
n=20 
Controls 
n=9 
Difference between 
iRBD and controls 
P value 
Left 
Substantia 
nigra  
0·156 
(0·134) 
0·003 
(0·095) 
0·153 
(0·055 to 0·250) 
0·003 - - - - 
Right 
Substantia 
nigra 
0·140 
(0·175) 
0·019 
(0·130) 
0·121 
(-0·007 to 0·250) 
0·064 - - - - 
Left Putamen  0·115 
(0·152) 
0·069 
(0·129) 
0·047 
(-0·068 to 0·161) 
0·41 0·0099 
(0·002) 
0·0131 
(0·001) 
-0·0032 
(-0·0044 to -0·0021) 
<0·0001 
Right Putamen  0·140 
(0·159) 
0·095 
(0·125) 
0·044 
(-0·074 to 0·163) 
0·45 0·0098 
(0·002) 
0·0130 
(0·001) 
-0·0032 
(-0·0044 to -0·0020) 
<0·0001 
Left caudate -0·143 
(0·147) 
-0·219 
(0·191) 
0·076 
(-0·053 to 0·205) 
0·24 0·0102 
(0·002) 
0·0114 
(0·001) 
-0·0012 
(-0·0025 to 0·00006) 
0·06 
Right caudate -0·152 
(0·161) 
-0·177 
(0·137) 
0·024 
(-0·098 to 0·147) 
0·69 0·0104 
(0·002) 
0·0113 
(0·001) 
-0·0009 
(-0·002 to 0·0003) 
0·1 
 
Mean tracer uptake (BPND or Ki values) and standard deviation 
(SD) and mean difference with 95% confidence interval (95% 
CI). iRBD = idiopathic REM sleep behaviour disorder. 
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Table 3 
Number of iRBD patients with abnormal 11C-PK11195 BPND and 18F-
DOPA Ki values 
 
A threshold for abnormality in regional 11C-PK11195 binding and 
18F-DOPA uptake was defined as a statistical deviation from the 
norm. Briefly, regional 11C-PK11195 binding were classified as 
abnormal when the BPND was two or more standard deviations 
above the control mean (z-score ≥ 2) - the control values from 
both left and right side were averaged. Patients were 
classified as having abnormal regional 18F-DOPA uptake when 
their Ki values fell below two or more standard deviations 
from the controls mean value (z-score ≤ -2).25 iRBD = 
idiopathic REM sleep behaviour disorder. 
 
 
 Participants with iRBD (n= 20) 
Region 11C-PK11195 18F-DOPA 
 Left Right Bilateral Abnormal 
subjects 
Left Right Bilateral Abnormal 
subjects 
Substantia 
nigra 
5 
(25%) 
4 
(20%) 
2 
(10%) 
7 
(35%) 
- - - - 
Putamen 2 
(10%) 
2 
(10%) 
2 
(10%) 
2 
(10%) 
16 
(80%) 
16 
(80%) 
14 
(70%) 
18 
(90%) 
Caudate 1 
(5%) 
2 
(10%) 
1 
(5%) 
2 
(10%) 
6 
(30%) 
7 
(35%) 
6 
(30%) 
7 
(35%) 
25 
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Figures 
Figure 1 
18F-DOPA and 11C-PK11195 images of an iRBD patient and control 
subjects. 
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Figure 2 
Correlations between tracer binding and regions of interests 
in iRBD patients (n=20) 
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Legends 
Figure 1. 18F-DOPA and 11C-PK11195 images of an iRBD patient and control 
subjects 
 
Images in the upper panel show striatal 18F-DOPA uptake in a 
patient with idiopathic rapid-eye-movement sleep behaviour 
disorder (iRBD)(right) and a healthy control (left). Images in 
the lower panel show 11C-PK11195 binding in the substantia 
nigra of an iRBD patient (right) and a healthy control (left). 
PET images are overlaid on the individual’s MR image.  
Scalebars indicates Ki values for 18F-DOPA and BPND for 11C-
PK11195.  
 
Figure 2. Correlations between tracer binding and regions of interests in iRBD 
patients (n=20) 
 
 
Each symbol represents values from 20 iRBD patients, left and 
right side is indicated by different colour. Pearson 
correlation coefficient is indicated for both left and right 
side. 
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Research in context  
Evidence before this study 
 
Prospective studies of idiopathic rapid-eye-movement sleep 
behaviour disorder (iRBD) patients have shown that up to 91% 
of cases develop the synucleinopathies Parkinson’s disease, 
dementia with Lewy bodies, or multiple system atrophy after 14 
years of follow-up.  Thus, iRBD is considered a harbinger of 
these conditions.  
We have reviewed the reported evidence of early neuroimaging 
changes detected in vivo in iRBD patients by searching PubMed 
in May 2017 for published articles containing the MESH terms 
“Parkinson disease”, “Lewy Body Disease”, “Multiple System 
Atrophy”, “REM sleep behaviour disorder”, “Positron-Emission 
Tomography”, “Tomography Emission-Computed Single-Photon”, 
“Magnetic Resonance Imaging”, and “Proton Magnetic Resonance 
Spectroscopy”.  
We found that previous neuroimaging studies consistently 
report the presence of nigrostriatal dopamine decrement in 
iRBD. Additionally, some studies observed relatively increased 
glucose metabolism and blood flow in the pons of iRBD 
patients. MRI changes in the brainstem have also been 
reported, and a single study observed microstructural changes 
related to neurodegeneration in the substantia nigra of iRBD 
patients. These neuroimaging observations combined with post-
mortem descriptions of Lewy pathology in the brainstem of iRBD 
30 
 
patients indicate the presence of an underlying 
neurodegenerative process. 
Studies in patients affected by neurodegenerative disorders 
and their animal models have implicated microglial activation 
as a characteristic feature of the neuropathological process.  
11C-PK11195 PET, an in vivo marker of translocator protein 
expressed by activated microglia cells, has shown raised 
nigrostriatal binding in patients with established 
synucleinopathies. Microglial activation may cause cell death 
and thus contribute to the development and progression of the 
neurodegenerative process and in the light of these 
observations, we hypothesized that microglial activation might 
also be increased in the nigrostriatal structures of iRBD 
patients.  
 
Added value of this study 
 
This is the first study in iRBD patients using in vivo PET 
imaging to investigate the occurrence of intrinsic 
neuroinflammation in the nigrostriatal system, a potential 
pathological mechanism contributing to the progression towards 
full-blown synucleinopathies. 11C-PK11195 PET, a marker of 
microglial activation, and 18F-DOPA PET, a marker of dopa 
decarboxylase activity, were used to investigate levels of 
nigrostriatal neuroinflammation and dopaminergic nigrostriatal 
function in iRBD patients, respectively. Significantly 
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increased levels of microglial activation were found in the 
substantia nigra of iRBD patients. This was correlated with 
increased levels of microglia activation in the ipsilateral 
putamen. Additionally, we found decreased 18F-DOPA uptake in 
the putamen bilaterally in the iRBD patients compared to 
controls.  
 
Implications of all available evidence 
 
This study presents the first in vivo observations indicating 
that increased microglial activation in iRBD is an early 
component in the neurodegenerative process along with 
nigrostriatal dopaminergic deficits. This finding marks 
microglial cells as a potential therapeutic target for future 
disease-modifying strategies, which could be tested to halt or 
delay progression of the underlying neurodegenerative process. 
Future follow-up studies may elucidate whether high levels of 
microglial activation are associated with a more rapid 
progression towards full-blown synucleinopathies and whether 
these imaging modalities are useful to monitor the effect of 
disease-modifying strategies.  
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